Last updated: August 1, 2026
MERSALYL-THEOPHYLLINE market dynamics and financial trajectory (revenue, pricing, exclusivity, and generic risk)
MERSALYL-THEOPHYLLINE is a fixed-dose combination of theophylline and mercurous salicylate (Mersalyl) sold as an oral product. Public, auditable market data for brand-level unit sales, wholesale acquisition cost (WAC), net price, and segment revenue is not available in the sources cited below. As a result, a complete financial trajectory cannot be constructed to the standard required for investment, licensing, or litigation decisions.
What is MERSALYL-THEOPHYLLINE and how is it positioned in the market?
MERSALYL-THEOPHYLLINE is a historical combination cough/bronchospasm product built around theophylline, a methylxanthine with narrow therapeutic index, used for obstructive airway disease in earlier practice patterns and, in many markets, displaced over time by safer bronchodilator options.
Therapeutic area and usage signals
- Theophylline is used in asthma/COPD airway disease management.
- The “Mersalyl” component (mercurous salicylate) reflects an older era of combination expectorant/anti-inflammatory approaches and is not a current standard-of-care driver in most major markets.
Market positioning implications
- Fixed-dose combinations containing theophylline typically face:
- clinical substitution toward bronchodilators and inhaled corticosteroid regimens,
- safety-driven prescribing changes (therapeutic window management),
- and generic commoditization pressures where the active ingredients are off-patent.
How do exclusivity and patent timelines shape MERSALYL-THEOPHYLLINE sales prospects?
A jurisdiction-specific exclusivity calendar requires:
- the exact national authorization dossier,
- the precise innovator and brand/label variants,
- Orange Book (US) or corresponding national registers (EU, UK, CA, AU, etc.),
- and formulation or method-of-use patent families tied to that label.
No such registry-backed, drug-specific data for MERSALYL-THEOPHYLLINE is provided in the cited sources.
Key market dynamic
For older combination products where the individual actives are off-patent, sales trajectories usually transition to:
- steady erosion after generic entry,
- pricing compression,
- and declining market share unless a brand is protected by label-specific formulation patents, manufacturing process IP, or prolonged regulatory exclusivity (which must be evidenced in authoritative listings).
What patent landscape typically protects theophylline combination products like MERSALYL-THEOPHYLLINE?
Without drug-specific patent numbers tied to the exact branded product, the only defensible statement is structural: protection, where present, is usually split across:
- drug substance or salt claims (often long expired for theophylline),
- formulation/excipient claims (granulation, release profile),
- manufacturing process claims,
- and sometimes method-of-use claims (dose regimens, therapeutic targets).
Where protection usually matters commercially
- If a brand has a unique formulation (e.g., modified release) it can slow substitution.
- If it is a simple immediate-release combination, generic entry tends to be faster and more complete.
What generic entry risks exist for MERSALYL-THEOPHYLLINE?
Generic risk is generally driven by whether:
- the branded product is simple immediate-release with standard excipients,
- generic listings can match strength, dosage form, and pharmaceutic availability,
- and whether regulators require bioequivalence for that combination.
Market dynamic
- Theophylline is widely manufactured and generic supply is common in many markets.
- Combination-brand survivals usually depend on continued local prescribing habits and distribution contracts, not on long-term patent leverage.
What is the Orange Book status of MERSALYL-THEOPHYLLINE?
No Orange Book listing can be cited from the provided sources. As a result, Orange Book exclusivity status and FDA-listed patents for the exact branded combination cannot be stated.
What FDA regulatory status applies to MERSALYL-THEOPHYLLINE and its competitors?
A branded FDA approval record and label history are not supplied in the cited sources for this specific product. Without that, FDA pathway (NDA vs ANDA), approval date, and labeling evolution cannot be verified.
How do pricing and reimbursement dynamics usually evolve for older theophylline combination brands?
In mature markets, older theophylline brands with no strong ongoing IP tend to experience:
- price decreases after generic entry,
- tighter formulary placement through managed-care contracting,
- and reduced payer preference for narrow therapeutic index oral products versus newer bronchodilator regimens.
Observed payer behavior across similar therapeutic categories
- Replacement by inhaled therapies (LABA/LAMA, ICS-containing regimens) reduces demand for systemic oral methylxanthines where clinically appropriate.
When does MERSALYL-THEOPHYLLINE lose exclusivity?
A verifiable “lose exclusivity” date is not provided in the cited sources. The product’s marketed exclusivity end date cannot be computed without:
- the earliest regulatory exclusivity start,
- the last relevant patent expiry or exclusivity milestone,
- and the applicable jurisdiction.
How does MERSALYL-THEOPHYLLINE compare with safer COPD/asthma therapies on market demand?
Clinically and commercially, theophylline products have faced:
- competition from inhaled bronchodilators and combination inhaler regimens,
- tighter safety monitoring in routine practice,
- and guideline-driven preference shifts toward inhaled therapies for long-term airway disease.
Commercial impact
- This substitution pattern reduces long-cycle demand growth and increases the likelihood that any brand revenue trajectory is dominated by generic and formulary headwinds rather than brand expansion.
What settlement, Paragraph IV, or biosimilar litigation affects theophylline combination products?
No drug-specific litigation records (US or other jurisdictions) tied to MERSALYL-THEOPHYLLINE are available in the cited sources. Therefore, settlement timing, generic launch sequencing, and court outcomes cannot be provided.
What manufacturing and IP barriers could delay generic substitution?
For combination oral products, the main barriers are typically:
- validated manufacturing controls,
- bioequivalence study feasibility,
- and any formulation IP tied to the exact branded product.
But for market trajectory modeling
Those barriers must be linked to evidence of:
- enforceable formulation patents,
- regulatory exclusivity,
- or documented ANDA stays.
No such evidence is provided in the cited sources.
Market trajectory scenarios for MERSALYL-THEOPHYLLINE: erosion vs niche retention
Given the absence of verified exclusivity, patent, FDA listing, or sales data in the cited sources, the only defensible scenario framework is structural:
Scenario A: Generic substitution dominates
- Price compression after generic availability.
- Declining share over time with residual demand concentrated in:
- legacy patients,
- limited local formularies,
- supply continuity advantages for branded supply chains.
Scenario B: Niche retention via local distribution and clinical inertia
- Lower-than-average erosion if the brand remains stocked and substitution is slow.
- Revenue becomes distribution-led rather than innovation-led.
Key points for financial trajectory modeling (what drives revenue slope)
Even without exact numbers, the slope is typically determined by:
- timing and breadth of generic availability,
- formulary status and payer tier placement,
- label stability (strength/dosage form),
- and safety-related prescribing patterns for oral theophylline.
Key Takeaways
- MERSALYL-THEOPHYLLINE is a historical fixed-dose theophylline combination product facing the same structural demand pressures as other theophylline brands: clinical substitution and generic erosion.
- A complete, evidence-backed financial trajectory (revenue, pricing, unit movement) and a precise exclusivity end date cannot be produced from the provided sources.
- Any “market outlook” conclusion for licensing or investment requires jurisdiction-specific regulatory listings and brand-level sales data tied to the exact formulation and strength.
FAQs
- Is MERSALYL-THEOPHYLLINE still prescribed in major markets, and what replaces it?
- Do generic versions of theophylline combinations require different bioequivalence considerations than monotherapy theophylline?
- What factors most influence payer formulary placement for oral theophylline products?
- How do narrow therapeutic index drugs affect prescribing and generic uptake in practice?
- What typical patent claim types (formulation vs method-of-use) matter most for fixed-dose combination brands?
References (APA)
- DailyMed. (n.d.). Drug label information database. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- European Medicines Agency. (n.d.). Human medicines: medicines search. https://www.ema.europa.eu/
- World Health Organization. (n.d.). ATC/DDD index. https://www.whocc.no/
